These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 2487913)
41. Long-term immunologic tolerance induction in chimeric mice after bone marrow transplantation across major histocompatibility barriers: persistent or redeveloping immunologic responsiveness after prolonged survival. Sugiura K; Yasumizu R; Iwai H; Inaba MM; Toki J; Ogura M; Hara I; Good RA; Ikehara S Thymus; 1991 Nov; 18(3):137-53. PubMed ID: 1838450 [TBL] [Abstract][Full Text] [Related]
42. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10). Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464 [TBL] [Abstract][Full Text] [Related]
43. Immune recovery after bone marrow transplantation. Lum LG Hematol Oncol Clin North Am; 1990 Jun; 4(3):659-75. PubMed ID: 2193017 [TBL] [Abstract][Full Text] [Related]
44. Establishing immunological tolerance through the induction of molecular chimerism. Bagley J; Bracy JL; Tian C; Kang ES; Iacomini J Front Biosci; 2002 May; 7():d1331-7. PubMed ID: 11991829 [TBL] [Abstract][Full Text] [Related]
45. The biology of bone marrow transplantation for severe combined immune deficiency. Parkman R Adv Immunol; 1991; 49():381-410. PubMed ID: 1677234 [No Abstract] [Full Text] [Related]
46. Kinetics of prevention of graft-versus-host disease and bone marrow rejection by ultraviolet B modulation of bone marrow inoculum. Oluwole SF; Engelstad K; Hardy MA Transplant Proc; 1992 Dec; 24(6):2858-9. PubMed ID: 1465974 [No Abstract] [Full Text] [Related]
52. Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance. Hu M; Kramer B; Zhang GY; Wang YM; Watson D; Howden B; McCowage G; Alexander IE; Gunning P; Alexander SI Transplantation; 2015 Dec; 99(12):2476-84. PubMed ID: 26177088 [TBL] [Abstract][Full Text] [Related]
53. Developmental immunotoxicology (DIT): windows of vulnerability, immune dysfunction and safety assessment. Dietert RR J Immunotoxicol; 2008 Oct; 5(4):401-12. PubMed ID: 19404874 [TBL] [Abstract][Full Text] [Related]
54. Mechanisms of graft failure after human marrow transplantation: a review. Hows JM Immunol Lett; 1991 Jul; 29(1-2):77-80. PubMed ID: 1916930 [TBL] [Abstract][Full Text] [Related]
55. Increased engraftment and GVHD after in utero transplantation of MHC-mismatched bone marrow cells and CD80low, CD86(-) dendritic cells in a fetal mouse model. Chou SH; Chawla A; Lee TH; Zhou Y; Busch MP; Balassanian R; Ferrell L; Cowan MJ Transplantation; 2001 Dec; 72(11):1768-76. PubMed ID: 11740386 [TBL] [Abstract][Full Text] [Related]
56. Specific prolongation of skin graft survival following retroviral transduction of bone marrow with an allogeneic major histocompatibility complex gene. Sykes M; Sachs DH; Nienhuis AW; Pearson DA; Moulton AD; Bodine DM Transplantation; 1993 Jan; 55(1):197-202. PubMed ID: 8420048 [TBL] [Abstract][Full Text] [Related]
57. Simultaneous donor bone marrow and cardiac transplantation: can tolerance be induced with the development of chimerism? Gammie JS; Pham SM Curr Opin Cardiol; 1999 Mar; 14(2):126-32. PubMed ID: 10191971 [TBL] [Abstract][Full Text] [Related]
58. Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow. Drobyski WR; Piaskowski V; Ash RC; Casper JT; Truitt RL Transplantation; 1990 Oct; 50(4):625-32. PubMed ID: 1699309 [TBL] [Abstract][Full Text] [Related]